{ "run": { "id": "cmnqz7occ00z0p65804k8wdjr", "region": "BR", "assetId": "cmnqz7oao00yip658itu955wx", "ticker": "RADL3", "snapshotId": "cmnqz7oay00yyp658hbxn4vvf", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T04:27:49.113Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnqz7oay00yyp658hbxn4vvf", "assetId": "cmnqz7oao00yip658itu955wx", "asOf": "2026-04-08T21:30:33.000Z", "snapshot": { "asOf": "2026-04-08T21:30:33.000Z", "quote": { "asOf": "2026-04-08T21:30:33.000Z", "open": 22.95, "price": 23.42, "dayLow": 22.7, "volume": 16798200, "dayHigh": 23.54, "currency": "BRL", "prevClose": 23.33, "week52Low": 12.81372553, "week52High": 27.42 }, "fundamentals": { "pe": 31.41094420600858, "beta": 0, "epsTTM": 0.746027, "fcfTTM": 954571000, "growth": { "epsYoy": 2.712, "revenueYoy": 3.3835385 }, "sector": "Consumo Não Cíclico", "margins": { "net": 0.029383725, "gross": 0.29298887, "operating": 0.062000886 }, "website": "https://www.rdsaude.com.br", "industry": "Medicamentos e Outros Produtos", "pegRatio": 0.11072002, "ebitdaTTM": 4756611000, "forwardPe": 0, "marketCap": 38936463383, "totalCash": 528739000, "totalDebt": 8148744000, "debtEquity": 1.1107934, "quickRatio": 0.5226758, "revenueTTM": 44250448000, "companyName": "Raia Drogasil S.A.", "priceToBook": 5.3220987, "currentRatio": 1.4620948, "dividendYield": 0.02511801686592656, "returnOnAssets": 0.051657468, "returnOnEquity": 0.17724219, "analystOpinions": 0, "businessSummary": "A RD Saúde (Raia Drogasil S.A.), listada na B3 sob o ticker RADL3, é uma varejista farmacêutica brasileira formada pela fusão entre Droga Raia e Drogasil em 2011. A companhia opera em escala nacional e mantém foco em medicamentos, produtos de saúde, higiene e conveniência.\n\nO negócio é estruturado em rede de lojas físicas, canais digitais e serviços de saúde adjacentes, com atuação multicanal para atendimento ao consumidor final. Além das bandeiras Raia e Drogasil, a empresa desenvolve iniciativas em ecossistema de saúde, incluindo serviços e soluções de jornada do paciente.\n\nA estratégia operacional combina expansão orgânica de lojas, ganho de produtividade, digitalização de vendas e integração logística para reduzir prazo de entrega e elevar recorrência de compra. O modelo prioriza alta capilaridade urbana e fortalecimento da base de clientes de longo prazo.\n\nNo mercado brasileiro, a R…", "enterpriseValue": 46662750000, "analystTargetLow": 0, "analystTargetHigh": 0, "analystTargetMean": 0, "fullTimeEmployees": 57708, "sharesOutstanding": 1752367400, "enterpriseToEbitda": 9.810083, "analystTargetMedian": 0, "enterpriseToRevenue": 1.0545148, "operatingCashflowTTM": 2430654000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T04:27:49.066Z" }, "results": [ { "id": "cmnqz7ocf00z6p658ycef219b", "runId": "cmnqz7occ00z0p65804k8wdjr", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"RADL3\",\"currency\":\"BRL\",\"current_price\":23.42,\"target_price_6m\":25.1,\"target_price_12m\":26.5,\"recommendation\":\"BUY\",\"confidence\":0.6,\"thesis_bullets\":[\"Leading Brazilian pharmacy retailer with national scale and strong brand moats\",\"PEG of 0.11 signals earnings growth materially outpacing current PE multiple\",\"EPS surged 271% YoY indicating margin recovery and operating leverage kicking in\",\"Digital and health-ecosystem initiatives diversify revenue beyond traditional retail\",\"Valuation at 31x PE is demanding and limits upside if growth disappoints\"],\"key_drivers\":[{\"driver\":\"Store expansion pipeline driving top-line growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating leverage improving thin net margins from 2.9%\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Digital channel penetration boosting same-store sales\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Health ecosystem services adding recurring revenue streams\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Elevated debt-to-equity of 1.11 raises interest cost sensitivity\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Brazilian Selic rate trajectory affecting WACC and consumer spending\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Competitive intensity from independent pharmacies and digital entrants\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory risk on drug pricing in Brazil\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Interest rate rises compressing multiples and increasing debt service burden\",\"Net margin of only 2.9% leaves little buffer for cost overruns\",\"Aggressive expansion could dilute returns on capital if execution slips\",\"Currency depreciation eroding purchasing power of BRL-denominated consumers\",\"Regulatory cap changes on pharmaceutical pricing in Brazil\"],\"assumptions\":{\"revenue_cagr_3y\":0.13,\"ebit_margin_target\":0.075,\"wacc\":0.13,\"terminal_multiple\":11.5},\"scenarios\":{\"bear\":{\"target_price\":19.5,\"prob\":0.2,\"notes\":\"Margin stagnation plus macro headwinds compress multiple to ~25x PE.\"},\"base\":{\"target_price\":26.5,\"prob\":0.55,\"notes\":\"Continued store expansion and margin recovery sustain mid-teens earnings growth.\"},\"bull\":{\"target_price\":31.0,\"prob\":0.25,\"notes\":\"Digital and ecosystem acceleration lifts margins and re-rates multiple toward 35x PE.\"}},\"method_notes\":\"Blended PE-forward and EV/EBITDA approach. 12M EPS est ~0.88 BRL on 18% earnings growth; base PE of ~30x yields ~26.5. Cross-checked via EV/EBITDA of 10-11x on projected EBITDA ~5.4B. 13% 12M expected return supports BUY. High PE keeps confidence moderate. Sell-side targets noted but not used as inputs. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "ai-equity-research-v1", "risks": [ "Interest rate rises compressing multiples and increasing debt service burden", "Net margin of only 2.9% leaves little buffer for cost overruns", "Aggressive expansion could dilute returns on capital if execution slips", "Currency depreciation eroding purchasing power of BRL-denominated consumers", "Regulatory cap changes on pharmaceutical pricing in Brazil" ], "ticker": "RADL3", "currency": "BRL", "scenarios": { "base": { "prob": 0.55, "notes": "Continued store expansion and margin recovery sustain mid-teens earnings growth.", "target_price": 26.5 }, "bear": { "prob": 0.2, "notes": "Margin stagnation plus macro headwinds compress multiple to ~25x PE.", "target_price": 19.5 }, "bull": { "prob": 0.25, "notes": "Digital and ecosystem acceleration lifts margins and re-rates multiple toward 35x PE.", "target_price": 31 } }, "confidence": 0.6, "assumptions": { "wacc": 0.13, "revenue_cagr_3y": 0.13, "terminal_multiple": 11.5, "ebit_margin_target": 0.075 }, "key_drivers": [ { "driver": "Store expansion pipeline driving top-line growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating leverage improving thin net margins from 2.9%", "impact": "HIGH", "direction": "POS" }, { "driver": "Digital channel penetration boosting same-store sales", "impact": "MED", "direction": "POS" }, { "driver": "Health ecosystem services adding recurring revenue streams", "impact": "MED", "direction": "POS" }, { "driver": "Elevated debt-to-equity of 1.11 raises interest cost sensitivity", "impact": "MED", "direction": "NEG" }, { "driver": "Brazilian Selic rate trajectory affecting WACC and consumer spending", "impact": "HIGH", "direction": "NEG" }, { "driver": "Competitive intensity from independent pharmacies and digital entrants", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory risk on drug pricing in Brazil", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended PE-forward and EV/EBITDA approach. 12M EPS est ~0.88 BRL on 18% earnings growth; base PE of ~30x yields ~26.5. Cross-checked via EV/EBITDA of 10-11x on projected EBITDA ~5.4B. 13% 12M expected return supports BUY. High PE keeps confidence moderate. Sell-side targets noted but not used as inputs. Not investment advice.", "current_price": 23.42, "recommendation": "BUY", "thesis_bullets": [ "Leading Brazilian pharmacy retailer with national scale and strong brand moats", "PEG of 0.11 signals earnings growth materially outpacing current PE multiple", "EPS surged 271% YoY indicating margin recovery and operating leverage kicking in", "Digital and health-ecosystem initiatives diversify revenue beyond traditional retail", "Valuation at 31x PE is demanding and limits upside if growth disappoints" ], "target_price_6m": 25.1, "target_price_12m": 26.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 50403, "createdAt": "2026-04-09T04:27:49.113Z", "usage": { "inputTokens": 3793, "outputTokens": 1849, "costUsd": 0.06519 } }, { "id": "cmnqz7ocf00z9p658lkejchel", "runId": "cmnqz7occ00z0p65804k8wdjr", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI_Equity_Research_Model\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"RADL3\",\n \"currency\": \"BRL\",\n \"current_price\": 23.42,\n \"target_price_6m\": 23.0,\n \"target_price_12m\": 22.5,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\"Steady revenue growth in defensive pharmaceutical retail.\", \"Margin improvement potential through operational efficiency.\", \"High valuation multiples relative to current earnings.\", \"Leveraged balance sheet poses financial risk.\", \"Digital transformation could drive future growth.\"],\n \"key_drivers\": [\n {\"driver\": \"Revenue Growth\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Operating Margin Expansion\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Digital Sales Penetration\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Competitive Pressure\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Regulatory Changes\", \"impact\": \"LOW\", \"direction\": \"NEG\"},\n {\"driver\": \"Debt Levels\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n {\"driver\": \"Expansion Strategy\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Economic Conditions\", \"impact\": \"LOW\", \"direction\": \"NEG\"}\n ],\n \"risks\": [\"Increased competition from online pharmacies.\", \"Regulatory changes affecting drug pricing.\", \"High debt increasing interest expense.\", \"Execution risk in digital initiatives.\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.035,\n \"ebit_margin_target\": 0.065,\n \"wacc\": 0.10,\n \"terminal_multiple\": 9.0\n },\n \"scenarios\": {\n \"bear\": {\"target_price\": 20.0, \"prob\": 0.2, \"notes\": \"Lower margins and higher competition.\"},\n \"base\": {\"target_price\": 22.5, \"prob\": 0.6, \"notes\": \"Steady growth with slight margin improvement.\"},\n \"bull\": {\"target_price\": 25.0, \"prob\": 0.2, \"notes\": \"Strong digital growth and market expansion.\"}\n },\n \"method_notes\": \"Valuation based on EV/EBITDA multiples and growth assumptions. Recommendation HOLD due to limited upside (-4% expected return) and balanced risk-reward. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "AI_Equity_Research_Model", "risks": [ "Increased competition from online pharmacies.", "Regulatory changes affecting drug pricing.", "High debt increasing interest expense.", "Execution risk in digital initiatives." ], "ticker": "RADL3", "currency": "BRL", "scenarios": { "base": { "prob": 0.6, "notes": "Steady growth with slight margin improvement.", "target_price": 22.5 }, "bear": { "prob": 0.2, "notes": "Lower margins and higher competition.", "target_price": 20 }, "bull": { "prob": 0.2, "notes": "Strong digital growth and market expansion.", "target_price": 25 } }, "confidence": 0.65, "assumptions": { "wacc": 0.1, "revenue_cagr_3y": 0.035, "terminal_multiple": 9, "ebit_margin_target": 0.065 }, "key_drivers": [ { "driver": "Revenue Growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating Margin Expansion", "impact": "MED", "direction": "POS" }, { "driver": "Digital Sales Penetration", "impact": "MED", "direction": "POS" }, { "driver": "Competitive Pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory Changes", "impact": "LOW", "direction": "NEG" }, { "driver": "Debt Levels", "impact": "HIGH", "direction": "NEG" }, { "driver": "Expansion Strategy", "impact": "MED", "direction": "POS" }, { "driver": "Economic Conditions", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on EV/EBITDA multiples and growth assumptions. Recommendation HOLD due to limited upside (-4% expected return) and balanced risk-reward. Not investment advice.", "current_price": 23.42, "recommendation": "HOLD", "thesis_bullets": [ "Steady revenue growth in defensive pharmaceutical retail.", "Margin improvement potential through operational efficiency.", "High valuation multiples relative to current earnings.", "Leveraged balance sheet poses financial risk.", "Digital transformation could drive future growth." ], "target_price_6m": 23, "target_price_12m": 22.5 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 363, "createdAt": "2026-04-09T04:27:49.113Z", "usage": { "inputTokens": 2266, "outputTokens": 4544, "costUsd": 0.002543 } }, { "id": "cmnqz7ocf00z7p658hyeiyax3", "runId": "cmnqz7occ00z0p65804k8wdjr", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Equity Analyst\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"RADL3\",\"currency\":\"BRL\",\"current_price\":23.42,\"target_price_6m\":24.00,\"target_price_12m\":24.50,\"recommendation\":\"HOLD\",\"confidence\":0.7,\"thesis_bullets\":[\"Premium valuation at 31x P/E leaves limited room for multiple expansion.\",\"Store expansion continues but revenue growth has slowed to low single digits.\",\"Solid ROE of 17.7 percent demonstrates efficient capital allocation and profitability.\",\"Digital initiatives and health services provide long-term ecosystem optionality.\",\"High debt-to-equity ratio increases sensitivity to Brazilian interest rate fluctuations.\"],\"key_drivers\":[{\"driver\":\"Store expansion rate\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Same-store sales growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Selic interest rate\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Digital channel penetration\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Generic drug mix\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Labor and rental inflation\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regional competition\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Slower-than-expected maturation of new store openings.\",\"Sustained high interest rates pressuring net income via financial expenses.\",\"Increased competition leading to gross margin compression.\",\"Regulatory changes in drug pricing adjustments by CMED.\"],\"assumptions\":{\"revenue_cagr_3y\":0.08,\"ebit_margin_target\":0.065,\"wacc\":0.115,\"terminal_multiple\":10.0},\"scenarios\":{\"bear\":{\"target_price\":16.50,\"prob\":0.25,\"notes\":\"Growth stalls and margins compress leading to a P/E de-rating.\"},\"base\":{\"target_price\":24.50,\"prob\":0.55,\"notes\":\"Steady expansion and slight margin improvement maintain current multiples.\"},\"bull\":{\"target_price\":30.80,\"prob\":0.20,\"notes\":\"Digital health ecosystem accelerates growth and drives multiple expansion.\"}},\"method_notes\":\"Valuation based on a 10-year DCF and target EV/EBITDA of 10x. The 12M target of 24.50 BRL implies ~5% upside, justifying a HOLD rating given the premium 31x P/E and slowing near-term growth. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "AI Equity Analyst", "risks": [ "Slower-than-expected maturation of new store openings.", "Sustained high interest rates pressuring net income via financial expenses.", "Increased competition leading to gross margin compression.", "Regulatory changes in drug pricing adjustments by CMED." ], "ticker": "RADL3", "currency": "BRL", "scenarios": { "base": { "prob": 0.55, "notes": "Steady expansion and slight margin improvement maintain current multiples.", "target_price": 24.5 }, "bear": { "prob": 0.25, "notes": "Growth stalls and margins compress leading to a P/E de-rating.", "target_price": 16.5 }, "bull": { "prob": 0.2, "notes": "Digital health ecosystem accelerates growth and drives multiple expansion.", "target_price": 30.8 } }, "confidence": 0.7, "assumptions": { "wacc": 0.115, "revenue_cagr_3y": 0.08, "terminal_multiple": 10, "ebit_margin_target": 0.065 }, "key_drivers": [ { "driver": "Store expansion rate", "impact": "HIGH", "direction": "POS" }, { "driver": "Same-store sales growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Selic interest rate", "impact": "MED", "direction": "NEG" }, { "driver": "Digital channel penetration", "impact": "MED", "direction": "POS" }, { "driver": "Generic drug mix", "impact": "MED", "direction": "POS" }, { "driver": "Labor and rental inflation", "impact": "MED", "direction": "NEG" }, { "driver": "Regional competition", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on a 10-year DCF and target EV/EBITDA of 10x. The 12M target of 24.50 BRL implies ~5% upside, justifying a HOLD rating given the premium 31x P/E and slowing near-term growth. Not investment advice.", "current_price": 23.42, "recommendation": "HOLD", "thesis_bullets": [ "Premium valuation at 31x P/E leaves limited room for multiple expansion.", "Store expansion continues but revenue growth has slowed to low single digits.", "Solid ROE of 17.7 percent demonstrates efficient capital allocation and profitability.", "Digital initiatives and health services provide long-term ecosystem optionality.", "High debt-to-equity ratio increases sensitivity to Brazilian interest rate fluctuations." ], "target_price_6m": 24, "target_price_12m": 24.5 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 29189, "createdAt": "2026-04-09T04:27:49.113Z", "usage": { "inputTokens": 2491, "outputTokens": 564, "costUsd": 0.01175 } }, { "id": "cmnqz7ocf00z5p658qgwjb6z1", "runId": "cmnqz7occ00z0p65804k8wdjr", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"RADL3\",\"currency\":\"BRL\",\"current_price\":23.42,\"target_price_6m\":24.1,\"target_price_12m\":24.4,\"recommendation\":\"HOLD\",\"confidence\":0.62,\"thesis_bullets\":[\"Defensive pharmacy demand supports resilient sales across softer macro periods.\",\"National scale and omnichannel logistics reinforce share and convenience.\",\"Strong cash generation helps fund expansion despite thin retail margins.\",\"Current valuation already prices much of execution and digital upside.\",\"Leverage, competition, and promotions limit near-term rerating potential.\"],\"key_drivers\":[{\"driver\":\"Store opening cadence\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Same-store prescription growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Digital and loyalty penetration\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Gross margin mix\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"SG&A operating leverage\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Competition and promotions\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Leverage and interest burden\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Premium earnings multiple\",\"impact\":\"HIGH\",\"direction\":\"NEG\"}],\"risks\":[\"Stronger promotional intensity compresses margins.\",\"Consumer weakness hurts front-store categories.\",\"New-store ramp execution disappoints.\",\"Higher rates pressure valuation multiples.\",\"Regulatory or tax changes affect pricing.\"],\"assumptions\":{\"revenue_cagr_3y\":8.5,\"ebit_margin_target\":6.6,\"wacc\":11.8,\"terminal_multiple\":10.0},\"scenarios\":{\"bear\":{\"target_price\":20.8,\"prob\":0.25,\"notes\":\"Traffic softens and promotions rise, limiting margin progression.\"},\"base\":{\"target_price\":24.4,\"prob\":0.5,\"notes\":\"Steady expansion and modest productivity gains sustain valuation.\"},\"bull\":{\"target_price\":27.6,\"prob\":0.25,\"notes\":\"Better digital mix and execution support faster earnings growth.\"}},\"method_notes\":\"Blended EV/EBITDA and FCF-yield approach using snapshot TTM data plus labeled assumptions; no sell-side targets used. Snapshot quote fields kept authoritative. HOLD fits mixed fundamentals and ~4% 12M upside. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "OpenAI o3", "risks": [ "Stronger promotional intensity compresses margins.", "Consumer weakness hurts front-store categories.", "New-store ramp execution disappoints.", "Higher rates pressure valuation multiples.", "Regulatory or tax changes affect pricing." ], "ticker": "RADL3", "currency": "BRL", "scenarios": { "base": { "prob": 0.5, "notes": "Steady expansion and modest productivity gains sustain valuation.", "target_price": 24.4 }, "bear": { "prob": 0.25, "notes": "Traffic softens and promotions rise, limiting margin progression.", "target_price": 20.8 }, "bull": { "prob": 0.25, "notes": "Better digital mix and execution support faster earnings growth.", "target_price": 27.6 } }, "confidence": 0.62, "assumptions": { "wacc": 11.8, "revenue_cagr_3y": 8.5, "terminal_multiple": 10, "ebit_margin_target": 6.6 }, "key_drivers": [ { "driver": "Store opening cadence", "impact": "HIGH", "direction": "POS" }, { "driver": "Same-store prescription growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Digital and loyalty penetration", "impact": "MED", "direction": "POS" }, { "driver": "Gross margin mix", "impact": "MED", "direction": "POS" }, { "driver": "SG&A operating leverage", "impact": "HIGH", "direction": "POS" }, { "driver": "Competition and promotions", "impact": "HIGH", "direction": "NEG" }, { "driver": "Leverage and interest burden", "impact": "MED", "direction": "NEG" }, { "driver": "Premium earnings multiple", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Blended EV/EBITDA and FCF-yield approach using snapshot TTM data plus labeled assumptions; no sell-side targets used. Snapshot quote fields kept authoritative. HOLD fits mixed fundamentals and ~4% 12M upside. not investment advice", "current_price": 23.42, "recommendation": "HOLD", "thesis_bullets": [ "Defensive pharmacy demand supports resilient sales across softer macro periods.", "National scale and omnichannel logistics reinforce share and convenience.", "Strong cash generation helps fund expansion despite thin retail margins.", "Current valuation already prices much of execution and digital upside.", "Leverage, competition, and promotions limit near-term rerating potential." ], "target_price_6m": 24.1, "target_price_12m": 24.4 }, "errorsJson": { "attempts": [ { "error": "sanity_error: hold_scenario_return_too_directional: HOLD requires probability-weighted scenario return within +/-6%.", "attempt": 0, "rawOutputTruncated": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T21:30:33.000Z\",\"ticker\":\"RADL3\",\"currency\":\"BRL\",\"current_price\":23.42,\"target_price_6m\":24.1,\"target_price_12m\":24.7,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"Defensive pharmacy demand supports resilient sales through softer macro.\",\"National scale and omnichannel logistics help protect market share.\",\"Healthy FCF generation offsets thin retail margins.\",\"Premium valuation already discounts much of expansion and digital upside.\",\"Leverage, competition, and reimbursement dynamics cap near-term rerating.\"],\"key_drivers\":[{\"driver\":\"Store opening cadence\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Same-store prescription growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Digital and loyalty penetration\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Gross margin mix\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Operating leverage on SG&A\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Competition and price discipline\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Leverage and interest burden\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Premium earnings multiple\",\"impact\":\"HIGH\",\"direction\":\"NEG\"}],\"risks\":[\"Faster margin…" } ], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0f260f8a78165acb0069d72cf8f1188193912d8d9fde6d7436", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 15139, "createdAt": "2026-04-09T04:27:49.113Z", "usage": { "inputTokens": 3004, "outputTokens": 1019, "costUsd": 0.019523 } }, { "id": "cmnqz7ocf00z8p658ni1fa1rv", "runId": "cmnqz7occ00z0p65804k8wdjr", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Blended DCF and Multiples\",\n \"as_of\": \"2026-04-08T21:30:33.000Z\",\n \"ticker\": \"RADL3\",\n \"currency\": \"BRL\",\n \"current_price\": 23.42,\n \"target_price_6m\": 25.8,\n \"target_price_12m\": 27.5,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Dominant position in Brazilian pharma retail with extensive network.\",\n \"Omnichannel strategy accelerates digital sales and loyalty.\",\n \"Scale advantages support gradual operating margin expansion.\",\n \"31x PE valuation offers limited safety if growth slows.\",\n \"Health services ecosystem provides long-term compounding potential.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Store expansion and capex execution\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Digital and omnichannel sales growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operating leverage and efficiency gains\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Consumer health spending trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Competition from regional chains\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Brazil interest rate volatility\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Drug pricing and regulation\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Supply chain cost management\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"High PE multiple compresses on growth miss\",\n \"Economic slowdown curbs consumer spending\",\n \"Rising competition erodes market share\",\n \"Debt burden in higher rate environment\",\n \"Regulatory caps on medicine prices\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 7.5,\n \"ebit_margin_target\": 7.0,\n \"wacc\": 9.8,\n \"terminal_multiple\": 15.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 20.5,\n \"prob\": 0.3,\n \"notes\": \"Weak economy and margin pressure lead to de-rating.\"\n },\n \"base\": {\n \"target_price\": 27.5,\n \"prob\": 0.5,\n \"notes\": \"Consistent execution on expansion and efficiency gains.\"\n },\n \"bull\": {\n \"target_price\": 33.0,\n \"prob\": 0.2,\n \"notes\": \"Accelerated share gains and health services success.\"\n }\n },\n \"method_notes\": \"3y DCF using revenue CAGR, EBIT target, WACC and terminal EV/EBIT multiple, cross-checked with peers. 17% 12M upside supports BUY per rubric. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T21:30:33.000Z", "model": "Blended DCF and Multiples", "risks": [ "High PE multiple compresses on growth miss", "Economic slowdown curbs consumer spending", "Rising competition erodes market share", "Debt burden in higher rate environment", "Regulatory caps on medicine prices" ], "ticker": "RADL3", "currency": "BRL", "scenarios": { "base": { "prob": 0.5, "notes": "Consistent execution on expansion and efficiency gains.", "target_price": 27.5 }, "bear": { "prob": 0.3, "notes": "Weak economy and margin pressure lead to de-rating.", "target_price": 20.5 }, "bull": { "prob": 0.2, "notes": "Accelerated share gains and health services success.", "target_price": 33 } }, "confidence": 0.62, "assumptions": { "wacc": 9.8, "revenue_cagr_3y": 7.5, "terminal_multiple": 15.5, "ebit_margin_target": 7 }, "key_drivers": [ { "driver": "Store expansion and capex execution", "impact": "HIGH", "direction": "POS" }, { "driver": "Digital and omnichannel sales growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating leverage and efficiency gains", "impact": "MED", "direction": "POS" }, { "driver": "Consumer health spending trends", "impact": "HIGH", "direction": "POS" }, { "driver": "Competition from regional chains", "impact": "MED", "direction": "NEG" }, { "driver": "Brazil interest rate volatility", "impact": "MED", "direction": "NEG" }, { "driver": "Drug pricing and regulation", "impact": "MED", "direction": "NEG" }, { "driver": "Supply chain cost management", "impact": "LOW", "direction": "POS" } ], "method_notes": "3y DCF using revenue CAGR, EBIT target, WACC and terminal EV/EBIT multiple, cross-checked with peers. 17% 12M upside supports BUY per rubric. not investment advice.", "current_price": 23.42, "recommendation": "BUY", "thesis_bullets": [ "Dominant position in Brazilian pharma retail with extensive network.", "Omnichannel strategy accelerates digital sales and loyalty.", "Scale advantages support gradual operating margin expansion.", "31x PE valuation offers limited safety if growth slows.", "Health services ecosystem provides long-term compounding potential." ], "target_price_6m": 25.8, "target_price_12m": 27.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "3026cf45-7972-9a1c-936a-862814eb49b3", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 24837, "createdAt": "2026-04-09T04:27:49.113Z", "usage": { "inputTokens": 2819, "outputTokens": 3860, "costUsd": 0.066357 } } ] } }